| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 Oxford University Press
ARTICLE |
Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma
Affiliations of authors: Division of Cancer Epidemiology and Genetics (LBT, DH, EG, MHG) and Division of Cancer Prevention (GMD), National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD; Princess Margaret Hospital, University of Toronto, Ontario, Canada (MG); Netherlands Cancer Institute, Amsterdam, The Netherlands (FEVL); Cancer Care Ontario, Toronto, Canada (EH); Uppsala University, Uppsala, Sweden (BG); Danish Cancer Society, Copenhagen, Denmark (MA, HS); Finnish Cancer Registry, Helsinki, Finland (EP); The University of Iowa, Iowa City, IA (CFL); Information Management Services, Rockville, MD (DP); The University of Texas M. D. Anderson Cancer Center, Houston, TX (SAS, MS); The Dr. Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands (MBVV); Helsinki University Central Hospital, Helsinki, Finland (TJ); International Epidemiology Institute, Rockville, MD and Vanderbilt University Cancer Center, Nashville, TN (JDB)
Correspondence to: Lois B. Travis, MD, National Cancer Institute, NIH, DHHS, EPS #7086, Bethesda, MD 20892 (e-mail: travisl{at}mail.nih.gov).
Background: Many women develop breast cancer after treatment for Hodgkin lymphoma (HL) at a young age. We estimated this future risk, taking into account age and calendar year of HL diagnosis, HL treatment information, population breast cancer incidence rates, and competing causes of death. Methods: Relative risks of breast cancer for categories defined by radiation dose to the chest (0, 20–<40 Gy, or 
40 Gy) and use of alkylating agents (yes or no) were estimated from a case–control study conducted within an international population-based cohort of 3817 female 1-year survivors of HL diagnosed at age 30 years or younger from January 1, 1965, through December 31, 1994. To compute cumulative absolute risks of breast cancer, we used modified standardized incidence ratios to relate cohort breast cancer risks to those in the general population, enabling application of population-based breast cancer rates, and we allowed for competing risks by using population-based mortality rates in female HL survivors. Results: Cumulative absolute risks of breast cancer increased with age at end of follow-up, time since HL diagnosis, and radiation dose. For an HL survivor who was treated at age 25 years with a chest radiation dose of at least 40 Gy without alkylating agents, estimated cumulative absolute risks of breast cancer by age 35, 45, and 55 years were 1.4% (95% confidence interval [CI] = 0.9% to 2.1%), 11.1% (95% CI = 7.4% to 16.3%), and 29.0% (95% CI = 20.2% to 40.1%), respectively. Cumulative absolute risks were lower in women treated with alkylating agents. Conclusions: Breast cancer projections varied considerably by type of HL therapy, time since HL diagnosis, and age at end of follow-up. These estimates are applicable to HL survivors treated with regimens of the past and can be used to counsel such patients and plan management and preventive strategies. Projections should be used with caution, however, in patients treated with more recent approaches, including limited-field radiotherapy and/or ovary-sparing chemotherapy.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Radiation Therapy in Hodgkin Disease: Why Risk a Pyrrhic Victory?
- Dan L. Longo
J Natl Cancer Inst 2005 97: 1394-1395.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  E. W. Blank, P.-Y. Wong, R. Lakshmanaswamy, R. Guzman, and S. Nandi Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats PNAS, March 4, 2008; 105(9): 3527 - 3532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ponzone and P. Sismondi Patients With Breast Cancer Are Unlikely to Benefit From Prophylactic Irradiation of the Contralateral Breast J. Clin. Oncol., February 20, 2008; 26(6): 1014 - 1015. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lee, M. Pintilie, D. C. Hodgson, P. E. Goss, and M. Crump Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma Ann. Onc., January 1, 2008; 19(1): 62 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Coursey, D. P. Frush, T. Yoshizumi, G. Toncheva, G. Nguyen, and S. B. Greenberg Pediatric Chest MDCT Using Tube Current Modulation: Effect on Radiation Dose with Breast Shielding Am. J. Roentgenol., January 1, 2008; 190(1): W54 - W61. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Travis Multiple Primary Cancers: An Overview of the National Cancer Institute's Surveillance, Epidemiology, and End Results Program ASCO Educational Book, January 1, 2008; 2008(1): 413 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Ng Second Cancers after Hodgkin's Lymphoma: Long-term Risks ASCO Educational Book, January 1, 2008; 2008(1): 418 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Gail, J. P. Costantino, D. Pee, M. Bondy, L. Newman, M. Selvan, G. L. Anderson, K. E. Malone, P. A. Marchbanks, W. McCaskill-Stevens, et al. Projecting Individualized Absolute Invasive Breast Cancer Risk in African American Women J Natl Cancer Inst, December 5, 2007; 99(23): 1782 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Maule, G. Scelo, G. Pastore, P. Brennan, K. Hemminki, E. Tracey, R. Sankila, E. Weiderpass, J. H. Olsen, M. L. McBride, et al. Risk of Second Malignant Neoplasms After Childhood Leukemia and Lymphoma: An International Study J Natl Cancer Inst, May 16, 2007; 99(10): 790 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Hodgson, E. S. Gilbert, G. M. Dores, S. J. Schonfeld, C. F. Lynch, H. Storm, P. Hall, F. Langmark, E. Pukkala, M. Andersson, et al. Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's Lymphoma J. Clin. Oncol., April 20, 2007; 25(12): 1489 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Mariotto, J. H. Rowland, L. A.G. Ries, S. Scoppa, and E. J. Feuer Multiple Cancer Prevalence: A Growing Challenge in Long-term Survivorship Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 566 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Saslow, C. Boetes, W. Burke, S. Harms, M. O. Leach, C. D. Lehman, E. Morris, E. Pisano, M. Schnall, S. Sener, et al. American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography CA Cancer J Clin, March 1, 2007; 57(2): 75 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Sanna, K Lorizzo, N Rotmensz, V Bagnardi, S Cinieri, M Colleoni, F Nole, and A Goldhirsch Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors Ann. Onc., February 1, 2007; 18(2): 288 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Castiglioni, M. Terenziani, M. L. Carcangiu, R. Miliano, P. Aiello, L. Bertola, T. Triulzi, P. Gasparini, T. Camerini, G. Sozzi, et al. Radiation Effects on Development of HER2-Positive Breast Carcinomas Clin. Cancer Res., January 1, 2007; 13(1): 46 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Travis Evaluation of the Risk of Therapy-Associated Complications in Survivors of Hodgkin Lymphoma Hematology, January 1, 2007; 2007(1): 192 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Haukvik, I Dieset, T Bjoro, H Holte, and S. Fossa Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma Ann. Onc., September 1, 2006; 17(9): 1428 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Gospodarowicz and R. M. Meyer The Management of Patients with Limited-Stage Classical Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 253 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Longo Radiation Therapy in Hodgkin Disease: Why Risk a Pyrrhic Victory? J Natl Cancer Inst, October 5, 2005; 97(19): 1394 - 1395. [Full Text] [PDF]
|
|